nach oben

Erschienen in:

21.02.2024 | Metastasen | Zertifizierte Fortbildung Neurologie

Neuroonkologie

Interdisziplinäre Behandlungsstrategien bei Hirnmetastasierung

verfasst von: PD Dr. med. Pia Zeiner, Prof. Dr. med. Claus Rödel, Prof. Dr. med. Marcus Czabanka, Prof. Dr. med. Joachim Steinbach

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 2/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Hirnmetastasen sind die häufigsten Hirntumoren im Erwachsenenalter. Die Standardtherapie umfasst neurochirurgische und strahlentherapeutische Ansätze sowie medikamentöse Therapien in Abstimmung auf den Primarius. Dabei gewinnen biologische und pharmakologische Aspekte, die spezifisch für das ZNS sind, zunehmend an Bedeutung. Dieser Artikel gibt einen Überblick über den aktuellen Therapiestandard. …

Ostrom QT, Wright CH. & Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27-42

Le Rhun E et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology. 2021;32:1332-47

Sperduto P W et al. Survival in Patients with Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020;38(32):3773-84

Soffietti R et al. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology. 2022;24:855-871

Boire A et al. Liquid biopsy in central nervous system metastases: A RANO review and proposals for clinical applications. Neuro-Oncology. 2019;21:571-83

Thon N et al. Neurosurgical interventions for cerebral metastases of solid tumors. Dtsch Arztebl Int. 2023;120:162-9

Vogelbaum MA. et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021;40:492-516

Yamamoto M et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017;99:31-40

Baschnagel AM et al. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery: Clinical article. J Neurosurg. 2013;119:1139-44

10.

Mahajan A et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1040-48

11.

Traylor JI et al. Fractionated stereotactic radiotherapy for local control of resected brain metastases. J Neurooncol. 2019;144:343-50

12.

Turner BE et al. Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Postresection Stereotactic Radiosurgery for Brain Metastases: A Multi- institutional Study of Interobserver Reliability HHS Public Access. Int J Radiat Oncol Biol Phys. 2020;106,579-86

13.

Ladbury C et al. Stereotactic Radiosurgery in the Management of Brain Metastases: A Case-Based Radiosurgery Society (RSS) Practice Guideline: Brain Metastasis SRS RSS Practice Guideline. Adv Radiat Oncol. 2023:101402

14.

Dharnipragada R et al. Preoperative Versus Postoperative Radiosurgery of Brain Metastases: A Meta-Analysis. World Neurosurg. 2024;182:35-41

15.

Das S et al. A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases. BMC Cancer. 2021;22:1368

16.

Brown PD et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease: a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049-60

17.

Brown PD et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology. 2020;38:1019-29

18.

Brastianos PK et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164-77

19.

Davies MA et al. Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial HHS Public Access Author manuscript. Lancet Oncol. 2017;18:863-73

20.

Gonzalez M et al. A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial) Journal of Clinical Oncology. 2019;37:TPS9600-TPS9600

21.

Zhao Y et al. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis. Int J Cancer. 2022;150:1318-28

22.

Murthy RK et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2019;382:597-609

23.

Pérez-García JM et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: DEBBRAH trial. Neuro Oncol. 2023; 25:157-66

24.

Bartsch R et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840-47

25.

Jacobson A, Hurvitz S A. Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases. Oncologist. 2022;27(Suppl 1):S3-4

26.

Jusino S, Fadul CE, Dillon P. Systematic review of the management of brain metastases from hormone receptor positive breast cancer. J Neurooncol. 2023;162(1):45-57

27.

Descourt R et al. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother. 2023;72:91-9

28.

Hou X et al. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. J Thorac Oncol. 2023;18:769-79

29.

Nadal E et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). Journal of Clinical Oncology. 2023;41:4478-85

30.

Tawbi HA et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692-704

31.

Pace A et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017;18: e330-40

32.

Schmitt J et al. Initial Cancer Treatment in Certified Versus Non-Certified Hospitals. Dtsch Arztebl Int. 2023;120:647-54

Titel: Neuroonkologie
Interdisziplinäre Behandlungsstrategien bei Hirnmetastasierung
verfasst von: PD Dr. med. Pia Zeiner
Prof. Dr. med. Claus Rödel
Prof. Dr. med. Marcus Czabanka
Prof. Dr. med. Joachim Steinbach
Publikationsdatum: 21.02.2024
Verlag: Springer Medizin
Schlagwörter: Metastasen
Hirntumoren
Zerebrale Metastasen
Operation von Metastasen
Tyrosinkinaseinhibitoren
Strahlentherapie
Internistische Arzneimitteltherapie
Mammakarzinom
Lungenkarzinome
Melanom
Melanom
NSCLC
NSCLC
Tyrosinkinaseinhibitoren
Neurologie
Psychiatrie und Psychosomatik
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 2/2024
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-024-3838-6

Antisense-Oligonukleotid reduziert die Konzentration von Tau-Protein im Liquor

Morbus Alzheimer
Kommentierte Studie

Die Schwelle für eine schwere Neutropenie könnte herabgesetzt werden

Schizophrenie
Kommentierte Studie

Kein Effekt auf den ALS-Verlauf

Amyotrophe Lateralsklerose
Kommentierte Studie

Subkutane Ketamingabe für behandlungsresistente Depression

Ketamin
Kommentierte Studie

Ketogene Diät bei Säuglingen und Kleinkindern: So wirksam wie Anfallssuppressiva?

Epilepsie
Kommentierte Studie

Neue Daten zur Sicherheit und Verträglichkeit von Ofatumumab

Ofatumumab
Neues aus der Industrie